Interleukin-17 promotes development of castration-resistant prostate cancer potentially through creating an immunotolerant and pro-angiogenic tumor microenvironment

Prostate

Volumn 74, Issue 8, 2014, Pages 869-879

  Zhang, Qiuyang ^a   Liu, Sen ^a   Zhang, Qingsong ^a   Xiong, Zhenggang ^a   Wang, Alun R ^a   Myers, Leann ^b   Melamed, Jonathan ^c   Tang, Wendell W ^d   You, Zongbing ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TULANE UNIVERSITY   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

castration resistant; interleukin 17; prostate cancer; tumor immunology; tumor microenvironment

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; MATRILYSIN; VASCULOTROPIN; Y BOX BINDING PROTEIN 1;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; IMMUNOLOGICAL TOLERANCE; INFLAMMATORY CELL; LYMPHOCYTE; MACROPHAGE; MALE; MOUSE; MOUSE MODEL; MOUSE MUTANT; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SUPPRESSOR CELL; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

CASTRATION-RESISTANT; INTERLEUKIN-17; PROSTATE CANCER; TUMOR IMMUNOLOGY; TUMOR MICROENVIRONMENT;

ANIMALS; IMMUNE TOLERANCE; INTERLEUKIN-17; MALE; MICE; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; ORCHIECTOMY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, INTERLEUKIN-17; TUMOR MICROENVIRONMENT;

EID: 84899586492     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22805     Document Type: Article

References (49)

1. Harris WP, Mostaghel EA, Nelson PS, Montgomery B,. Androgen deprivation therapy: Progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009; 6 (2): 76-85.
2. Newmark JR, Hardy DO, Tonb DC, Carter BS, Epstein JI, Isaacs WB, Brown TR, Barrack ER,. Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 1992; 89 (14): 6319-6323.
3. Mohler JL, Gregory CW, Ford OH III, Kim D, Weaver CM, Petrusz P, Wilson EM, French FS,. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10 (2): 440-448.
4. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo J,. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009; 69 (1): 16-22.
5. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H,. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994; 54 (20): 5474-5478.
6. Craft N, Shostak Y, Carey M, Sawyers CL,. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999; 5 (3): 280-285.
7. Debes JD, Schmidt LJ, Huang H, Tindall DJ,. p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res 2002; 62 (20): 5632-5636.
8. Jin RJ, Wang Y, Masumori N, Ishii K, Tsukamoto T, Shappell SB, Hayward SW, Kasper S, Matusik RJ,. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res 2004; 64 (15): 5489-5495.
9. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML,. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52 (24): 6940-6944.
10. July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME,. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002; 50 (3): 179-188.
11. Heidenberg HB, Bauer JJ, McLeod DG, Moul JW, Srivastava S,. The role of the p53 tumor suppressor gene in prostate cancer: A possible biomarker ? Urology 1996; 48 (6): 971-979.
12. Abate-Shen C, Banach-Petrosky WA, Sun X, Economides KD, Desai N, Gregg JP, Borowsky AD, Cardiff RD, Shen MM,. Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res 2003; 63 (14): 3886-3890.
13. Graff JR, Konicek BW, McNulty AM, Wang Z, Houck K, Allen S, Paul JD, Hbaiu A, Goode RG, Sandusky GE, Vessella RL, Neubauer BL,. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 2000; 275 (32): 24500-24505.
14. Cai C, Wang H, Xu Y, Chen S, Balk SP,. Reactivation of androgen receptor-regulated TMPRS S2: ERG gene expression in castration-resistant prostate cancer. Cancer Res 2009; 69 (15): 6027-6032.
15. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM,. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310 (5748): 644-648.
16. Shi XB, Tepper CG, White RW,. MicroRNAs and prostate cancer. J Cell Mol Med 2008; 12 (5A): 1456-1465.
17. Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P,. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res 2009; 69 (8): 3356-3363.
18. Corcoran NM, Costello AJ,. Interleukin-6: Minor player or starring role in the development of hormone-refractory prostate cancer ? BJU Int 2003; 91 (6): 545-553.
19. Lee LF, Louie MC, Desai SJ, Yang J, Chen HW, Evans CP, Kung HJ,. Interleukin-8 confers androgen-independent growth and migration of LNCaP: Differential effects of tyrosine kinases Src and FAK. Oncogene 2004; 23 (12): 2197-2205.
20. Onishi RM, Gaffen SL,. Interleukin-17 and its target genes: Mechanisms of interleukin-17 function in disease. Immunology 2010; 129 (3): 311-321.
21. Toy D, Kugler D, Wolfson M, Vanden Bos T, Gurgel J, Derry J, Tocker J, Peschon J,. Cutting edge: Interleukin 17 signals through a heteromeric receptor complex. J Immunol 2006; 177 (1): 36-39.
22. Haudenschild D, Moseley T, Rose L, Reddi AH,. Soluble and transmembrane isoforms of novel interleukin-17 receptor-like protein by RNA splicing and expression in prostate cancer. J Biol Chem 2002; 277 (6): 4309-4316.
23. Ely LK, Fischer S, Garcia KC,. Structural basis of receptor sharing by interleukin 17 cytokines. Nat Immunol 2009; 10 (12): 1245-1251.
24. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, Oliver P, Huang W, Zhang P, Zhang J, Shellito JE, Bagby GJ, Nelson S, Charrier K, Peschon JJ, Kolls JK,. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001; 194 (4): 519-527.
25. Hu Y, Ota N, Peng I, Refino CJ, Danilenko DM, Caplazi P, Ouyang W,. IL-17RC is required for IL-17A- and IL-17F-dependent signaling and the pathogenesis of experimental autoimmune encephalomyelitis. J Immunol 2010; 184 (8): 4307-4316.
26. You Z, Dong Y, Kong X, Zhang Y, Vessella RL, Melamed J,. Differential expression of IL-17RC isoforms in androgen-dependent and androgen-independent prostate cancers. Neoplasia 2007; 9 (6): 464-470.
27. You Z, Shi XB, DuRaine G, Haudenschild D, Tepper CG, Lo SH, Gandour-Edwards R, de Vere White RW, Reddi AH,. Interleukin-17 receptor-like gene is a novel antiapoptotic gene highly expressed in androgen-independent prostate cancer. Cancer Res 2006; 66 (1): 175-183.
28. Zhang Q, Liu S, Ge D, Xue Y, Xiong Z, Abdel-Mageed AB, Myers L, Hill SM, Rowan BG, Sartor O, Melamed J, Chen Z, You Z,. Interleukin-17 promotes formation and growth of prostate adenocarcinoma in mouse models. Cancer Res 2012; 72 (10): 2589-2599.
29. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS, Liu X,., Wu H,. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003; 4 (3): 209-221.
30. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R, Ward JM, Cardiff RD,. Prostate pathology of genetically engineered mice: Definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004; 64 (6): 2270-2305.
31. Didier DK, Schiffenbauer J, Woulfe SL, Zacheis M, Schwartz BD,. Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box. Proc Natl Acad Sci USA 1988; 85 (19): 7322-7326.
32. Lovett DH, Cheng S, Cape L, Pollock AS, Mertens PR,. YB-1 alters MT1-MMP trafficking and stimulates MCF-7 breast tumor invasion and metastasis. Biochem Biophys Res Commun 2010; 398 (3): 482-488.
33. Gimenez-Bonafe P, Fedoruk MN, Whitmore TG, Akbari M, Ralph JL, Ettinger S, Gleave ME, Nelson CC,. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate 2004; 59 (3): 337-349.
34. Toh Y, Pencil SD, Nicolson GL,. A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses. J Biol Chem 1994; 269 (37): 22958-22963.
35. Kai L, Wang J, Ivanovic M, Chung YT, Laskin WB, Schulze-Hoepfner F, Mirochnik Y, Satcher RL Jr, Levenson AS,. Targeting prostate cancer angiogenesis through metastasis-associated protein 1 (MTA1). Prostate 2011; 71 (3): 268-280.
36. Townsley FM, Aristarkhov A, Beck S, Hershko A, Ruderman JV,. Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase. Proc Natl Acad Sci USA 1997; 94 (6): 2362-2367.
37. Hao Z, Zhang H, Cowell J,. Ubiquitin-conjugating enzyme UBE2C: Molecular biology, role in tumorigenesis, and potential as a biomarker. Tumour Biol 2012; 33 (3): 723-730.
38. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Janne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS, Brown M,. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009; 138 (2): 245-256.
39. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H, Lotze MT,. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101 (7): 2620-2627.
40. Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze MT, Kolls JK, Sasaki H,. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 2005; 175 (9): 6177-6189.
41. Kanda N, Koike S, Watanabe S,. IL-17 suppresses TNF-alpha-induced CCL27 production through induction of COX-2 in human keratinocytes. J Allergy Clin Immunol 2005; 116 (5): 1144-1150.
42. Miura S, Tatsuguchi A, Wada K, Takeyama H, Shinji Y, Hiratsuka T, Futagami S, Miyake K, Gudis K, Mizokami Y, Matsuoka T, Sakamoto C,. Cyclooxygenase-2-regulated vascular endothelial growth factor release in gastric fibroblasts. Am J Physiol Gastrointest Liver Physiol 2004; 287 (2): G444-G451.
43. He D, Li H, Yusuf N, Elmets CA, Li J, Mountz JD,., Xu H,. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol 2010; 184 (5): 2281-2288.
44. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI,. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008; 181 (8): 5791-5802.
45. Redente EF, Dwyer-Nield LD, Merrick DT, Raina K, Agarwal R, Pao W, Rice PL, Shroyer KR, Malkinson AM,. Tumor progression stage and anatomical site regulate tumor-associated macrophage and bone marrow-derived monocyte polarization. Am J Pathol 2010; 176 (6): 2972-2985.
46. Hanahan D, Weinberg RA,. Hallmarks of cancer: The next generation. Cell 2011; 144 (5): 646-674.
47. Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, Ellis TM, Wojcik EM, Yang D, Flanigan RC, Waters WB, Kast WM, Kwon ED,. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA 2001; 98 (25): 14565-14570.
48. Morse MD, McNeel DG,. T cells localized to the androgen-deprived prostate are T(H) 1 and T(H) 17 biased. Prostate 2012; 72 (11): 1239-1247.
49. Liu L, Ge D, Ma L, Mei J, Liu S, Zhang Q, Ren F, Liao H, Pu Q, Wang T, You Z,. Interleukin-17 and prostaglandin E2 are involved in formation of an M2 macrophage-dominant microenvironment in lung cancer. J Thorac Oncol 2012; 7 (7): 1091-1100.